|

Tarlatamab Clinical Trials

18 actively recruiting trials across 8 locations

▲ +2 trials since August 2026

Also known as: AMG 757, AMG-757, AMG757, Anti-DLL3 x Anti-CD3 BiTE AMG 757, BiTE Antibody AMG 757 +6 more

Pipeline

Phase 1: 4Phase 2: 10Phase 3: 2Phase 1/2: 2

Top Sponsors

Amgen4
University of Arizona1
University Health Network, Toronto1
National Taiwan University Hospital1
Memorial Sloan Kettering Cancer Center1

Indications

Cancer18
Lung Cancer12
Small Cell Lung Cancer4
Extensive Stage-small Cell Lung Cancer2
Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma1

Other10 trials

A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

Phase 2

Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

Phase 1/2

Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

Phase 2

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

Phase 2

Study of How Safe and Effective Tarlatamab is in Brain Cancers

Phase 2

Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients

Phase 2

Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status

Phase 2

Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)

Phase 2

Tarlatamab for SCLC Brain Metastases

Phase 2

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Phase 3

Gilbert, Arizona1 trial

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Banner MD Anderson Cancer Center

Phase 1

Goodyear, Arizona1 trial

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

City of Hope Cancer Center Phoenix

Phase 1

Tucson, Arizona1 trial

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Arizona Cancer Center at UMC North/University Medical Center

Phase 1/2

Los Angeles, California1 trial

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

University of Southern California, Norris Comprehensive Cancer Center

Phase 1

San Diego, California1 trial

A Study of Tarlatamab for People With Prostate Cancer

UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only)

Phase 2

Stanford, California1 trial

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

GSK Investigational Site

Phase 1

Orlando, Florida1 trial

Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

University of Florida Health Cancer Center at Orlando Health

Phase 3

Columbus, Ohio1 trial

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.